FDA Approves MannKind’s Inhaled Insulin for Children

What’s happening

The FDA approved MannKind Corporation's inhaled insulin for children with diabetes.

The treatment allows insulin to be inhaled rather than injected, providing another option for young patients who may struggle with regular injections.

What’s changing / Business impact

The approval expands treatment options in pediatric diabetes care and could increase adoption of alternative insulin delivery methods.

Why this matters

Many children dislike or fear frequent injections. Alternative delivery systems may improve treatment adherence and quality of life.